U18666A, an intra-cellular cholesterol transport inhibitor, inhibits dengue virus entry and replication

Antiviral Research

Volumn 93, Issue 1, 2012, Pages 191-198

  Poh, Mee Kian ^a,b,c   Shui, Guanghou ^b   Xie, Xuping ^a   Shi, Pei Yong ^a   Wenk, Markus R ^b,c   Gu, Feng ^a  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antiviral; Cholesterol; Dengue virus; Fatty acids; U18666A

Indexed keywords

3BETA (2 DIETHYLAMINOETHOXY)ANDROST 5 EN 17 ONE; CHOLESTEROL; FATTY ACID;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BIOSYNTHESIS; CHOLESTEROL INTAKE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG EFFECT; ENDOSOME; FATTY ACID SYNTHESIS; LYSOSOME; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS REPLICATION;

4-BUTYROLACTONE; ANDROSTENES; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; CHOLESTEROL; CRICETINAE; DENGUE VIRUS; DRUG SYNERGISM; ENDOSOMES; FATTY ACID SYNTHETASE COMPLEX; HUMANS; LYSOSOMES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

DENGUE VIRUS;

EID: 84355162292     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.11.014     Document Type: Article

References (40)

1. Bader T., Fazili J., Madhoun M., Aston C., Hughes D., Rizvi S., Seres K., Hasan M. Fluvastatin inhibits hepatitis C replication in humans. Am. J. Gastroenterol. 2008, 103(6):1383-1389.
2. Cannon B., Lewis A., Metze J., Thiagarajan V., Vaugh M.V., Somerharju P., Virtanen J., Huang J., Cheng K.H. Cholesterol supports headgroup superlattice domain formation in fluid phospholipid/cholesterol bilayers. J. Phys. Chem. 2006, 110(12):6339-6350.
3. Chambers T.J., Monath T.P. The Flavivirus: Pathogenesis and Immunity 2003, Elsevier Academic Press, pp. 60.
4. Chang J., Wang L., Ma D., Qu X., Guo H., Xu X., Mason P.M., Bourne N., Moriarty R., Gu B., Guo J.T., Block T.M. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob. Agents Chemother. 2009, 53(40):1501-1508.
5. Chen S.T., Lin Y.L., Huan M.T., Wu M.F., Cheng S.C., Lei H.Y., Lee C.K., Chiou T.W., Wong C.H., Hsieh S.L. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 2008, 453(7195):672-676.
6. Costin J.M., Jenwitheesuk E., Lok S.M., Hunsperger E., Conrads K.A., Fontaine K.A., Rees C.R., Rossmann M.G., Isern S., Samudrala R., Michael S.F. Structural optimization and de novo design of dengue virus entry inhibitory peptides. PLoS Negl. Trop. Dis. 2010, 4(6):e721.
7. Desplanques A.S., Pontes M., De Corte N., Verheyen N., Nauwynck H.J., Vercauteren D., Favoreel H.W. Cholesterol depletion affects infectivity and stability of pseudorabies virus. Virus Res. 2010, 152(1-2):180-183.
8. Gibbons R.V., Vaughn D.W. Dengue: an escalating problem. BMJ 2002, 324(7353):1563-1566.
9. Goldstein J.L., Brown M.S. Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulated the plasma cholesterol. J. Lipid Res. 1984, 25(13):1450-1461.
10. Goncalvez A.P., Engle R.E., St Claire M., Purcell R.H., Lai C.J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. 2007, 104:9422-9427.
11. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health social and economic problem in the 21st century. Trends Microbiol. 2002, 10:100-103.
12. Halstead S.B. In vivo enhancement of Dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 1979, 140:527-533.
13. Heaton N.S., Perera R., Berger K.L., Khadka S., Lacount D.J., Kuhn R.J., Randall G. Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc. Natl. Acad. Sci. U S A 2010, 107(40):17345-17350.
14. Helenius A., Kartenbeck J., Simons K., Fries E. On the entry of Semliki forest virus into BHK-21 cells. J. Cell Biol. 1980, 84(2):404-420.
15. Huang Q., Shen H., Shui G., Wenk M.R., Ong C. Emodin inhibits tumor cell adhesion through disruption of the membrane lipid raft-associated integrin signaling pathway. Cancer Res. 2006, 66(11):5807-5815.
16. Kruger P., Fitzsimmons K., Cook D., Jones M., Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteremia. Intensive Care Med. 2006, 32:75-79.
17. Lange Y., Ye J., Ridney M., Steck T.L. Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. J. Lipid Res. 1999, 40(12):2264-2270.
18. Latour D.R., Jekle A., Javanbhakht H., Henningsen R., Gee P., Lee I., Tran P., Ren S., Kutach A.K., Harris S.F., Wang S.M., Lok S.J., Shaw D., Li J., Heilek G., Klumpp K., Swinney D.C., Deval J. Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7-deza-adenosine triphosphate. Antiviral Res. 2010, 87(2):213-222.
19. Lee C.J., Lin H.R., Liao C.L., Lin Y.L. Cholesterol effectively blocks entry of flavivirus. J. Virol. 2008, 82(13):6470-6480.
20. Liang P.H., Cheng W.C., Lee Y.L., Yu H.P., Wu Y.T., Lin Y.L., Wong C.H. Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and ostearthritis. Chembiochem 2006, 7(1):165-173.
21. Liscum L., Faust J.R. The intracellular transport of low density lipoprotein-derived cholesterol is inhibited in Chinese hamster ovary cells cultured with 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one. J. Biol. Chem. 1989, 264(20):11796-11806.
22. Mackenzie J.M., Khromykh A.A., Parton R.G. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell Host Microbe 2007, 2(4):229-239.
23. Medigeshi G.R., Hirsch A.J., Streblow D.N., Nikolich-Zugich J., Nelson J.A. West Nile virus entry required cholesterol-rich membrane microdomains and is independent of alphavbeta3 integrin. J. Virol. 2008, 82(11):5212-5219.
24. Ng C.Y., Gu F., Phong W.Y., Chen Y.L., Lim S.P., Davidson A., Vasudevan S.G. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA. Antiviral Res. 2007, 76(3):222-231.
25. Niyomrattanakit P., Chen Y.L., Dong H., Yin Z., Qing M., Glickman J.F., Lin K., Mueller D., Voshol H., Lim J.Y., Nilar S., Keller T.H., Shi P.Y. Inhibition of dengue virus polymerase by blocking the RNA tunnel. J. Virol. 2010, 84(11):5678-5686.
26. Oh J., Hegele R.A. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect. Dis. 2007, 7(12):787-796.
27. Pastorino B., Nougairède A., Wurtz N., Gould E., de Lamballerie X. Role of host cell factors in flavivirus infection: implications for pathogenesis and development of antiviral drugs. Antiviral Res. 2010, 87(3):281-291.
28. Poh M.K., Yip A., Zhang S., Priestle J.P., Ma N.L., Smit J.M., Wilschut J., Shi P.Y., Wenk M.R., Schul W. A small molecule fusion inhibitor of dengue virus. Antiviral Res. 2009, 84(3):260-266.
29. Reyes-Del V.J., Chávez-Salinas S., Medina F., Del Angel R.M. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. J. Virol. 2005, 79(8):4557-4567.
30. Cenedella Richard J. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids 2009, 44:477-487.
31. Rothwell C., Lebreton A., Young Ng C., Lim J.Y., Liu W., Vasudevan S., Labow M., Gu F., Gaither L.A. Cholesterol biosynthesis modulation regulated dengue viral replication. Virology 2009, 389(1-2):8-19.
32. Samsa M.M., Mondotte J.A., Iglesias N.G., Assunção-Miranda I., Barbosa-Lima G., Da Poian A.T., Bozza P.T., Gamarnik A.V. Dengue virus capsid protein usurps lipid droplets for viral particle formation. PLoS Pathog. 2009, 5(10):e1000632.
33. Schmidt A.G., Yang P.L., Harrison S.C. Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate. PloS Pathog. 2010, 6(4):e1000851.
34. Schmitt L., Tampé R. Structure and mechanism of ABC transporters. Curr. Opin. Struct. Biol. 2002, 12:754-760.
35. Sexton R.C., Panini S.R., Azran F., Rudney H. Effects of 3 beta-[2-(diethylamino)ethoxy]androst-5-en-17-one on the synthesis of cholesterol and ubiquinone in rat intestinal epithelial cell cultures. Biochemistry 1983, 22(25):5687-5692.
36. Sidorkiewicz M., Józwiak B., Durys B., Majda-Stanislawska E., Piekarska A., Kosciuk N., Ciechowicz J., Majewska E., Bartkowiak J. Mevalonate pathway modulation is associated with hepatitis C virus RNA presence in peripheral blood mononuclear cells. Virus Res. 2009, 145(1):141-144.
37. Subramanya S., Kim S.S., Abraham S., Yao J., Kumar M., Kumar P., Haridas V., Lee S.K., Shultz L.D., Greiner D., Manjunath N., Shankar P. Targeted delivery of small interfering RNA to human dendritic cells to suppress dengue virus infection and associated proinflammatory cytokine production. J. Virol. 2010, 84(5):2490-2501.
38. Syed G.H., Amako Y., Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol. Metab. 2010, 21(1):33-40.
39. Wang Q.Y., Patel S.J., Vangrevelinghe E., Xu H.Y., Rao R., Jaber D., Schul W., Gu F., Heudi O., Ma N.L., Poh M.K., Phong W.Y., Keller T.H., Jacoby E., Vasudeven S.G. A small-molecule dengue virus entry inhibitor. Antimicrob. Agents Chemother. 2009, 53(5):1823-1831.
40. Yin Z., Chen Y.L., Schul W., Wang Q.Y., Gu F., Duraiswamy J., Kondreddi R.R., Niyomrattanaki P., Lakshminarayana S.B., Goh A., Xu H.Y., Liu W., Liu B., Lim J.Y., Ng C.Y., Qing M., Lim C.C., Yip A., Wang G., Chan W.L., Tan H.P., Lin K., Zhang B., Zhou G., Bernard K.A., Garrett C., Beltz K., Dong M., Weaver M., He H., Pichota A., Dartois V., Keller T.H., Shi P.Y. An adenosine nucleoside inhibitor of dengue virus. Proc. Natl. Acad. Sci. U S A 2009, 106(48):20435-20439.